IQVIA HOLDINGS INC. (IQV) Operating Margin
- Operating margin · 12 months: Value 13.23%; Formula and calculation Operating income / revenue. Period ending 2026-03-31..
Operating margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 13.23% | Operating income / revenue. Period ending 2026-03-31. $2.20B ÷ $16.63B × 100 ≈ 13.23% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 2.20B USD | Operating Income (Loss) |
| Revenue | 16.63B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 1.99B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2.20B | $16.63B | (m) | (m) | $1.99B | 13.23% |
| 2025-12-31 | $2.18B | $16.31B | (m) | (m) | $2.00B | 13.38% |
| 2025-09-30 | $2.18B | $15.90B | (m) | (m) | $1.98B | 13.71% |
| 2025-06-30 | $2.18B | $15.70B | (m) | (m) | $1.99B | 13.87% |
| 2025-03-31 | $2.19B | $15.50B | (m) | (m) | $1.99B | 14.14% |
| 2024-12-31 | $2.20B | $15.40B | (m) | (m) | $1.99B | 14.29% |
| 2024-09-30 | $2.08B | $15.31B | (m) | (m) | $2.10B | 13.56% |
| 2024-06-30 | $2.01B | $15.15B | (m) | (m) | $2.08B | 13.25% |
| 2024-03-31 | $2.01B | $15.07B | (m) | (m) | $2.05B | 13.35% |
| 2023-12-31 | $1.98B | $14.98B | (m) | (m) | $2.05B | 13.19% |
| 2023-09-30 | $1.85B | $14.86B | (m) | (m) | $2.08B | 12.49% |
| 2023-06-30 | $1.85B | $14.68B | (m) | (m) | $2.10B | 12.57% |
| 2023-03-31 | $1.77B | $14.49B | (m) | (m) | $2.10B | 12.25% |
| 2022-12-31 | $1.80B | $14.41B | (m) | (m) | $2.07B | 12.48% |
| 2022-09-30 | $1.88B | $14.31B | (m) | (m) | $2.03B | 13.16% |
| 2022-06-30 | $1.71B | $14.14B | (m) | (m) | $2.01B | 12.12% |
| 2022-03-31 | $1.55B | $14.03B | (m) | (m) | $2.01B | 11.02% |
| 2021-12-31 | $1.39B | $13.87B | (m) | (m) | $1.96B | 10.04% |
| 2021-09-30 | $1.22B | $13.54B | (m) | (m) | $1.91B | 9.01% |
| 2021-06-30 | $1.10B | $12.93B | (m) | (m) | $1.88B | 8.54% |
| 2021-03-31 | $880.00M | $12.01B | (m) | (m) | $1.82B | 7.32% |
| 2020-12-31 | $731.00M | $11.36B | (m) | (m) | $1.79B | 6.44% |
| 2020-09-30 | $608.00M | $10.96B | (m) | (m) | $1.78B | 5.55% |
| 2020-06-30 | $625.00M | $10.94B | (m) | (m) | $1.72B | 5.71% |
| 2020-03-31 | $760.00M | $11.16B | (m) | (m) | $1.72B | 6.81% |
| 2019-12-31 | $777.00M | $11.09B | (m) | (m) | $1.73B | 7.01% |
| 2019-09-30 | $818.00M | $10.88B | (m) | (m) | $1.69B | 7.52% |
| 2019-06-30 | $795.00M | $10.71B | (m) | (m) | $1.73B | 7.43% |
| 2019-03-31 | $768.00M | $10.53B | (m) | (m) | $1.72B | 7.29% |
| 2018-12-31 | $741.00M | $10.41B | (m) | (m) | $1.72B | 7.12% |
| 2018-09-30 | $730.00M | $10.28B | (m) | (m) | $1.73B | 7.10% |
| 2018-06-30 | $744.00M | $10.15B | (m) | (m) | $1.69B | 7.33% |
| 2018-03-31 | $700.00M | $9.94B | (m) | (m) | $1.64B | 7.04% |
| 2017-12-31 | $719.00M | $9.74B | (m) | (m) | $1.60B | 7.38% |
| 2017-09-30 | $661.00M | $9.50B | (m) | (m) | $1.53B | 6.96% |
| 2017-06-30 | $632.00M | $8.53B | (m) | (m) | $1.34B | 7.41% |
| 2017-03-31 | $631.00M | $7.71B | (m) | (m) | $1.19B | 8.18% |
| 2016-12-31 | $642.00M | $6.88B | (m) | (m) | $1.01B | 9.33% |
| 2016-09-30 | $675.29M | $6.06B | (m) | (m) | $944.85M | 11.14% |
| 2016-06-30 | $674.54M | $5.99B | (m) | (m) | $951.57M | 11.26% |
| 2016-03-31 | $682.19M | $5.88B | (m) | (m) | $926.89M | 11.60% |
| 2015-12-31 | $646.61M | $5.74B | (m) | $3.34M | $920.99M | 11.27% |
| 2015-09-30 | $627.56M | $5.63B | (m) | (m) | $901.97M | 11.15% |
| 2015-06-30 | $609.68M | $5.60B | (m) | (m) | $889.59M | 10.88% |
| 2015-03-31 | $592.29M | $5.50B | (m) | (m) | $882.70M | 10.77% |
| 2014-12-31 | $590.39M | $5.46B | (m) | $5.79M | $882.34M | 10.81% |
| 2014-09-30 | $558.47M | $5.43B | (m) | (m) | $890.08M | 10.29% |
| 2014-06-30 | $534.59M | $5.22B | (m) | (m) | $870.63M | 10.23% |
| 2014-03-31 | $488.48M | $5.18B | (m) | (m) | $880.45M | 9.43% |
| 2013-12-31 | $462.33M | $5.10B | (m) | $4.96M | $860.51M | 9.07% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $396.44M | $4.87B | (m) | $10.43M | $817.75M | 8.15% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $345.25M | $4.33B | (m) | $9.99M | $762.30M | 7.98% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |